Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most extracted claims (efficacy quantifiers, specific timing, and detailed diary and dosing/decision guidance) are reported as not supported by the provided label excerpts, indicating substantial deviation from on-label prescribing information as supplied.
Category Scores
Accurate Statements
Aimovig is indicated for preventive treatment of migraine in adults.
Supported by label section 1 excerpt: 'AIMOVIG is indicated for the preventive treatment of migraine in adults.'
Unsupported Statements
Aimovig (erenumab) reduces migraine frequency for many patients.
Evaluator indicates only partial support; provided excerpts do not quantify 'many patients' or explicitly state migraine frequency reduction with that wording.
Studies show 50% of users see at least 50% fewer migraine days after 3-6 months.
Evaluator reports absent from provided label excerpts; no responder threshold or timing (3-6 months) shown.
Recording migraine start/end times and duration is recommended for a migraine diary while on Aimovig.
Evaluator reports absent from provided label excerpts (diary-specific instructions not shown).
Recording pain severity on a 1-10 scale is recommended for a migraine diary while on Aimovig.
Evaluator reports absent from provided label excerpts.
Recording symptoms such as nausea, light/sound sensitivity, and aura is recommended for a migraine diary while on Aimovig.
Evaluator reports absent from provided label excerpts.
Recording triggers such as stress, foods, sleep changes, and weather is recommended for a migraine diary while on Aimovig.
Evaluator reports absent from provided label excerpts.
Recording Aimovig dose date and any injection-site reactions is recommended for a migraine diary while on Aimovig.
Evaluator reports absent from provided label excerpts as diary instruction guidance.
Recording rescue medications used (e.g., triptans) and their effect is recommended for a migraine diary while on Aimovig.
Evaluator reports absent from provided label excerpts.
Recording overall function impact (work/sleep missed) is recommended for a migraine diary while on Aimovig.
Evaluator reports absent from provided label excerpts.
Most patients see changes by month 1 when tracking pre- and post-Aimovig.
Evaluator reports absent from provided label excerpts; no 'most patients' or 'month 1' time-to-effect language shown.
Full effects of Aimovig take 3 months.
Evaluator reports absent from provided label excerpts; no 'full effects' at 3 months shown.
Aimovig dose adjustments may involve 70 mg versus 140 mg.
Evaluator reports absent from provided label excerpts; dosing amounts not shown.
Doctors may use diary data to make dose tweaks (70 mg vs 140 mg) or switch treatment.
Evaluator reports absent from provided label excerpts; no labeling support for diary-driven decision rules or the cited dose values.
If no improvement after 3 months, tracking can indicate the treatment is not effective for the patient.
Evaluator reports absent from provided label excerpts; no 3-month decision rule or use of tracking as an effectiveness determination shown.
Commonly noticed patterns on Aimovig include fewer but longer attacks initially.
Evaluator reports absent from provided label excerpts; no such attack-pattern description supported.
Commonly noticed patterns on Aimovig include reduced need for acute medications.
Evaluator reports absent from provided label excerpts.
There can be rebound if triggers are ignored (e.g., poor sleep).
Evaluator reports absent from provided label excerpts; rebound tied to trigger-ignoring/sleep not supported.
Aimovig rarely causes rebound headaches.
Evaluator reports absent from provided label excerpts; no rebound headache discussion or 'rarely' quantification shown.
Medication-overuse headache can mimic rebound headaches.
Evaluator reports absent from provided label excerpts; relationship between medication-overuse headache and rebound headaches not shown.
Contradictions
Important Omissions
Evaluation cannot audit high-priority label content for the response (e.g., contraindications, boxed warnings, and detailed warnings/precautions, plus drug interactions and specific populations) because the prompt does not provide the AI-generated response text and does not include the actual FDA label text for those sections.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Multiple claims introduce specific dosing/decision rules and detailed monitoring/diary guidance that are reported as unsupported by the provided label excerpts. While these are not direct contradictions, they may promote off-label or non-labeled clinical workflows and overconfident efficacy/time-to-effect statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Large proportion of extracted claims are unsupported by the provided prescribing information excerpts, including specific efficacy thresholds/timelines and dosing/diary-based decision guidance.
Suggested Improvement
Limit claims to what is explicitly supported by the provided label excerpts (e.g., general indication). Remove or rewrite unsupported details (50% responder threshold, month 1/3-month timing, specific 70 mg vs 140 mg adjustments, and diary-based decision rules).